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Abstract 
Objectives 
Cognition is a new treatment target to aid functional recovery and enhance quality of life for patients 
with bipolar disorder. The International Society for Bipolar Disorders (ISBD) Targeting Cognition 
Task Force aimed to develop consensus-based clinical recommendations on whether, when and how to 
assess and address cognitive impairment.  
Methods 
The task force, consisting of 19 international experts from nine countries, discussed the challenges and 
recommendations in a face-to-face meeting, telephone conference call and email exchanges. 
Consensus-based recommendations were achieved through these exchanges with no need for formal 
consensus methods.  
Results 
The identified questions were: (I) Should cognitive screening assessments be routinely conducted in 
clinical settings? (II) What are the most feasible screening tools? (III) What are the implications if 
cognitive impairment is detected? (IV) What are the treatment perspectives? Key recommendations are 
that clinicians: (I) formally screen cognition in partially or fully remitted patients whenever possible, 
(II) use brief, easy-to-administer tools such as the Screen for Cognitive Impairment in Psychiatry and 
Cognitive Complaints in Bipolar Disorder Rating Assessment, (III) evaluate the impact of medication 
and comorbidity, refer patients for comprehensive neuropsychological evaluation when clinically 
indicated, and encourage patients to build cognitive reserve. Regarding question (IV), there is limited 
evidence for current evidence-based treatments but intense research efforts are underway to identify 
new pharmacological and/or psychological cognition treatments. 
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Conclusions 
This task force paper provides the first consensus-based recommendations for clinicians on whether, 
when, and how to assess and address cognition, which may aid patients’ functional recovery and 
quality of life.  
Key words: Cognitive impairment, bipolar disorder, screening, neuropsychological, recommendations    
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1. Introduction  
Functional recovery and quality of life are important new treatment targets for patients with bipolar 
disorder (BD). While sustained symptomatic remission is an achievable goal with current 
pharmacological and psychological treatments, patients often do not recover full functional capacity, 
including work and social life. Indeed, quality of life is not merely the inverse of affective symptoms 
but also involves patients’ perceptions of their position in life in the context of their culture, values and 
personal aspirations (1). Poor life quality in BD is therefore closely linked to patients’ lower academic 
attainment and vocational function (2-4), high unemployment rates (5;6), and problems with household 
and community functioning (7). This has led to growing consensus that clinical remission ─ i.e., feeling 
well ─ is not a sufficient treatment goal: Patients also need to do well and recover functionally to 
achieve good quality of life (8).  
Persistent cognitive impairments across memory, attention, processing speed and executive function 
during periods of remission are directly related to poor quality of life (9) and socio-occupational 
outcome in BD (10-13). In fact, meta-analytic evidence indicates that memory and executive function 
are among the strongest contributors to occupational outcome in BD with greater impact than residual 
mood symptoms (13;14).  According to meta-analytic evidence, cognitive impairment in the remitted 
phase of BD is on average of a moderate effect size (15). However, recent studies revealed substantial 
cognitive heterogeneity in remitted BD patients: 12-40% of patients present global cognitive 
impairments across several domains, 29-40% show selective deficits in attention and psychomotor 
speed, and 32-48% are relatively ‘cognitively intact’ in comparison with norms (16-18). Importantly, 
patients with either global or selective cognitive impairments reported poorer quality of life, more 
perceived stress and lower vocational function than patients who were cognitively intact despite 
comparable levels of residual mood symptoms (18;19). It is therefore imperative to identify patients 
with persistent cognitive impairment, to characterize the pattern of their impairments, and to implement 
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strategies for remediating these deficits to improve the clinical management of BD. To this end, there is 
a need for consensus on whether and how to screen for and treat cognitive impairment in clinical 
practice.  
The International Society for Bipolar Disorders (ISBD) convened an expert task force in September 
2016 under the lead of Dr. Miskowiak with the aim of developing (I) a consensus-based guidance paper 
for the methodology and design of cognition trials in bipolar disorder for pharmacological and non-
pharmacological interventions, (II) a clinical recommendations paper for clinicians on how to address 
cognitive impairments in their patients, and (III) an educational patient booklet with information about 
cognitive impairment and pragmatic strategies for compensating for these in daily life. A paper 
addressing goal (I) was recently published in Bipolar Disorders (20). This specific paper addresses goal 
(II), developing consensus-based clinical recommendations by this ISBD task force that can be used by 
clinicians to guide their choices on whether, when and how to assess and address cognition in their 
patients.  
 
2. Methods 
The ISBD Targeting Cognition Task Force was initiated by Dr. Miskowiak in collaboration with Drs. 
Kessing and Vieta. It consists of 19 international experts in the field of cognition in mood disorders 
from the following nine countries (in alphabetical order): Brazil, Canada, Colombia, Denmark, Japan, 
New Zealand, Spain, United Kingdom, and United States of America. Members of the task force were 
selected based upon their expertise and include several members of a previous ISBD Cognition Task 
Force (21).  
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The process of the task force 
The task force work on goal (II) was initiated with a face-to-face meeting between task force members 
during the ISBD Congress in Washington DC in May 2017. During the meeting, the task force 
reviewed, expanded and agreed upon a series of key questions and tentative recommendations to be 
addressed in the clinical guidance paper. This was followed up by a telephone conference in May 2017 
for the task force members who had been unable to attend the ISBD congress. During the conference 
call, task force members discussed the identified clinical questions identified by Dr Miskowiak and 
associated recommendations. Consensus on the recommendations was reached through subsequent 
email exchanges between the task force members. The use of formal consensus methods was deemed 
unnecessary given high agreement amongst the task force members. 
 
3. Results: task force recommendations  
(I) Should cognitive screening assessments be implemented in the clinical management of bipolar 
disorder? 
Objective and subjective cognitive impairment 
The first questions addressed by the task force were: Should objective cognitive screening assessments 
with a short cognitive screening battery be recommended in addition to assessment of patients’ self-
reported cognitive difficulties? If so, should objective assessments be conducted for all patients, or only 
for those with either subjective cognitive complaints and/or occupational difficulties? 
There was strong agreement among task force members that qualified mental health professionals 
trained in cognitive screening assessment should conduct formal assessment of cognition for all adult 
patients in partial or full remission (e.g., a Hamilton Depression Rating Scale [HDRS] Score <14), 
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whenever possible. Assessment of cognition in clinically stable, at least partially remitted patients ─ 
ideally not before 2-3 months after a mood episode ─ enables detection of ‘trait-related’ cognitive 
deficits; i.e., deficits that do not result from acute mood symptoms but persist long-term and hamper 
patients’ work capacity and social life (10;12;13). The recommendation to screen and track cognition in 
all (partially) remitted patients is based on the evidence for poor correlation between subjective and 
objective cognitive impairment (22-25). This implies that it is not always the patients with the most 
subjective complaints who show greatest objective impairments and vice versa. Indeed, patients’ insight 
into their own cognitive abilities relies on several factors, including metacognitive capacity and 
severity of mood symptoms (26). Since 30-50% remitted patients are objectively cognitively intact in 
comparison with norms despite subjective cognitive complaints (16;18;19), relying purely on 
subjectively reported difficulties could lead to a high false positive rate.  At the same time, subjective 
assessments would also miss a considerable group of patients with unreported objective cognitive 
impairments due to poor insight or limited metacognitive capacity (27). Specifically, patients with BD 
may underreport difficulties within processing speed, attention and executive function domains (26). 
This is in keeping with emerging evidence that deficits in processing speed and attention domains are 
often mistaken for memory problems because failure to pay attention to and process information 
hampers subsequent recall of this information (28). Objective assessment of cognition is therefore 
necessary for correct identification of patients with cognitive impairment.  
Notwithstanding the importance of objective cognition assessments, it is also essential to evaluate 
patients’ subjectively experienced cognitive problems and/or work difficulties that may originate from 
objective cognitive deficits. Specifically, patient-reported cognitive difficulties in daily life situations 
and/ or decreased work capacity are crucial for the clinical meaningfulness of implementing strategies 
to compensate for or treat cognitive impairment. Consequently, cognition assessments should include 
both objective and subjective measures.  Finally, patients with cognitive performance in the normal 
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range, but who had high premorbid function, may be experiencing impairment relative to their true 
abilities even if this cannot be detected with a cognitive screening tool (where cut-offs for impairment 
are based on norms). Therefore, clinicians should also take into consideration patients’ educational and 
occupational attainment as a proxy for their premorbid function. Without this consideration, clinicians 
may erroneously relay the idea to patients that they are not experiencing cognitive challenges and not 
adjusting their treatment given unobserved decline. 
Brief cognitive screening 
Brief cognitive screening is valuable for three key reasons: (i) to detect cognitive impairment, (ii) to 
identify those who are relatively cognitively intact in comparison with norms, and (iii) to track 
cognition over time. First, screening for objective cognitive impairment is clinically important for 
patients with symptoms of depression or mania close to clinical threshold, since these patients tend to 
display greater subjective problems than objective impairment (26). Objective neurocognitive 
screening assessment can clarify whether their subjective cognitive difficulties and/or socio-
occupational problems are a consequence of objective cognitive impairment or secondary to other 
factors, such as residual mood symptoms or difficulties applying cognitive skills in complex daily life. 
This information can guide treatment selection to target either residual mood symptoms or cognition. 
Further, objective cognitive screening in patients with poor insight due to executive dysfunction (29) 
may clarify the extent to which objective cognitive deficits are contributing to any observed socio-
occupational problems. Since the mean age of BD onset is in the late teens to early twenties (30), 
persistent cognitive impairments can be detrimental for academic achievement, early occupational 
function and interpersonal relations. Hence, detection of cognitive impairment after (partial) remission 
in newly diagnosed patients may help patients identify and compensate for cognitive difficulties to 
maintain their educational or occupational functions, thus leading to better prognosis and quality of life 
(see discussion of cognitive reserve under point III). In patients later in the course of illness with more 
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substantial functional impairments, cognitive screening assessments are also valuable as they clarify if 
their functional issues are at least partially rooted in cognitive deficits. This may inform compensation 
strategies and cognitive/ functional rehabilitation interventions (see clinical implications and treatment 
perspectives under points III and IV).  
Second, objective cognition assessments may be useful in the management of patients presenting with 
concerns over ‘neuroprogression’ or dementia. A cognition assessment will enable clinicians to identify 
the 30-50% of patients who despite such potential concerns are objectively cognitively intact. Objective 
‘proof’ that their cognitive capacity is within the normal range can provide great relief and comfort for 
these patients and their relatives. Nevertheless, the results of a brief cognitive screening test should 
always be interpreted with caution and be considered in the context of the particular clinical 
presentation.  
Third, implementation of cognition assessments enables clinicians to track patients’ cognition over 
time in response to new treatments or new illness episodes. In particular, assessment of whether there is 
an objective change in cognition when patients have achieved (partial) remission after a medication 
switch may be particularly useful in cases where patients experience cognitive side-effects of their 
medication. If objective assessments reveal no cognitive change over time, this would provide an 
objective reference point for patients that reduces patients’ concerns about cognitive side-effects. In 
this way, cognitive screening assessments may aid treatment adherence (31) and thus indirectly 
improve patients’ prognosis. On the other hand, if cognition assessments do reveal cognitive decline in 
response to a new treatment, this could inform a change of the treatment plan to reduce the cognitive 
side-effects. For elderly patients, tracking cognition may be particularly useful in determining whether 
cognitive decline could be indicative of dementia onset. In such cases, patients should be referred to a 
complete diagnostic assessment. The frequency should be individualized, but ideally assessments 
should be made at least every 5 years or whenever there is a reason to anticipate the assessment (a 
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change in functioning or increased cognitive complaints, for example). However, major impediments 
for the detection of cognitive change are the uncertain reliability of test results and practice effects (32). 
Several psychometric approaches have been developed to determine ‘true’ or clinically significant 
change at the level of the individual patient (32). However, at this point, normative ‘cognitive change 
data’ are limited or unavailable for the SCIP (35) or other potential prospective cognitive screening 
tools in BD. This is an area of growing research and more specific guidelines are likely to become 
available to guide clinicians in their assessment of cognitive change within the next few years. 
 
(II) What are the most feasible cognition screening tools in bipolar disorder? 
A cognitive screening tool should be brief, easy and cost-effective for clinicians given time constraints 
and resource restrictions that make referral to a neuropsychologist untenable in most cases. There was 
consensus among task force members that the optimal way would be to have a simple, freely available 
“online package” which clinicians could use for all clinically stable adult patients in partial or full 
remission. Such a tool should include a few neurocognitive tests combined with questions about 
cognitive difficulties in daily life and mood status. Since there is currently no such validated online 
cognition screener for bipolar disorder, the Task Force agreed to explore the possibility of developing 
such a tool as a next goal. Until such a tool is available, the recommendations are to use available 
paper-and-pencil tools that are validated for detection of cognitive impairment in bipolar disorder. Two 
particularly feasible, easy-to-administer tools are the Screen for Cognitive Impairment in Psychiatry 
(SCIP; (33)) and the Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA; (34)). 
Both tools are short and feasible and have been shown in several studies to have high internal 
consistency, retest reliability and concurrent validity (24;34-37).  
Screen for Cognitive Impairment in Psychiatry 
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The SCIP is a brief cognitive screening tool consisting of five short objective tests of cognition that can 
be administered bedside in approximately 10-15 minutes and exists in three parallel versions to allow 
for repeated testing. It provides a quick quantification of significant difficulties with verbal working 
memory, verbal learning and memory, verbal fluency, and psychomotor speed and has high decision 
validity in patients with bipolar disorder (i.e., high sensitivity and specificity for cognitive impairment). 
The SCIP exists in several languages (in alphabetical order): Chinese (Mandarin), Danish, English, 
French, German, Italian, Japanese, Persian, Portuguese, Russian, and Spanish. The Danish, English, 
French, and German versions have been validated to detect cognitive impairment and exist with their 
respective norm data sets and respective cut-offs for cognitive impairment, whereas the Chinese, 
Italian, Japanese, Persian, Portuguese, and Russian versions exist in beta-versions (i.e., translations in 
need of further beta testing). These versions of SCIP (including beta-versions) can be obtained free of 
charge by clinicians who treat patients with bipolar disorder from the ISBD website (URL). Notably, 
the Spanish version of the SCIP is only commercially available via TEA Ediciones 
(web.teaediciones.com).  
Cognitive Complaints in Bipolar Disorder Rating Assessment  
The COBRA is a subjective cognitive impairment rating scale for patients with bipolar disorder that 
consists of 16 questions about cognitive difficulties in daily life scenarios (e.g., ‘Do you find it hard to 
concentrate when reading a book or a newspaper?’, ‘Do you have difficulties to find objects of daily 
use (keys, glasses, wristwatch…)?’, ‘Do you have the feeling that you do not finish what you begin?’). 
Despite general poor correlation between subjective and objective measures of cognition (22-25), the 
COBRA has shown some correlation with objective memory and executive function (24;34;36;37). 
However, when used alone, the sensitivity and specificity of the COBRA for objective cognitive 
impairment is suboptimal (i.e., below 70%) (24) and the instrument should therefore ideally be used in 
combination with an objective cognition measure such as the SCIP. The COBRA ─ and suggested cut-
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offs for cognitive impairment ─ is available from the ISBD website in the following languages (in 
alphabetical order): Chinese, Danish, English, Japanese and Spanish. An alternative to the COBRA is 
the Lithium Battery-Clinical (38), a list of recommendations for clinical assessment of subjective 
cognitive difficulties. For example, clinicians are encouraged to ask patients about their cognitive 
function if patients do not present spontaneous complaints, to discuss the multifactorial influences on 
perceived impairment, including the influence of mood symptoms, and to track subjective cognitive 
function over time (38).   
Cut-offs for impairment 
Importantly, cut-offs for impairment on the SCIP and the COBRA should only be used as ‘rough 
guides’ and should always be considered in the context of patient demographics, mood state and 
external outcome, such as ability to work, drive, and live independently. For the SCIP, it may be 
advisable to use a somewhat more conservative cut-off (i.e., lower SCIP total score) for cognitive 
impairment in older age patients than the published norm material  (24;35) given the age-related 
cognitive decline (39), which is potentially accelerated in mood disorders (40). Further, bipolar 
disorder in older age is associated with greater prevalence of dementia compared with the general 
population (41;42). An international expert group within the ISBD therefore recently recommended 
that clinicians screen cognition in older age patients using dementia sensitive instruments, such as the 
Mini Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) (43). Other 
dementia sensitive screening tests may also be used, such as the Addenbrooke's Cognitive Examination 
(ACE-R) and the Short Cognitive Performance Test (SKT). These instruments may be particularly 
suitable in cases where dementia is suspected because of ceiling effects in better functioning and/or 
younger patients.  In addition, given the potential complexity of differentiating the cognitive deficits in 
late-life BD from those associated with various types of dementia, referral for full neuropsychological 
evaluation would be recommended in some of these cases. 
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While the current norm material in some studies is based on age-, gender- and IQ-matched healthy 
control groups, it is not age-corrected per se, which reflects a current limitation that may be overcome 
with further normative data collection. Ongoing research aims to determine the optimal SCIP and 
COBRA cut-offs for cognitive impairment across a range of age-groups including older age patients. 
Another issue with using the published SCIP norms is that cognitive impairment may be difficult to 
detect in patients with substantial above-normal premorbid function. Thus, is logistically feasible, 
clinicians may consider cognitive impairment with reference to patients’ cognitive reserve as reflected 
by their educational level or general IQ. Since higher COBRA scores correlated with greater symptom 
severity (24), a more conservative cut-off (i.e. a higher COBRA score) for impairment may therefore 
be considered for patients with substantial subsyndromal symptoms. Finally, linking cognitive 
impairment to external outcomes is also important for guiding treatment steps when cognitive 
impairment is detected (see implications and treatment perspectives under points III and IV).  
Minimum tools  
In situations where it is not possible for clinicians to conduct the full SCIP and COBRA, or where these 
instruments are not available in the local language, the recommendation for ‘minimal assessments’ 
would be to talk with the patient about their cognitive abilities in daily life, asking them to give specific 
examples, and combine this interview with one or two SCIP subtests, such as the verbal fluency and 
coding tests (which can be easily administered in any language and require minimal time/ training). In 
particular, the SCIP coding test has shown sensitivity to cognitive change in response to medication 
effects and aging, and is therefore the recommended ‘minimum tool’ to track cognition over time. 
However, for screening purposes, cutting down the SCIP to 1-2 subtests would be at the expense of 
assessment validity, since the tool is already short (<15 minutes) and constitutes a minimum of what 
can be considered a valid cognition assessment.  
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Limitations of cognitive screeners 
While brief cognitive screening tools can be administered by qualified mental health professionals after 
minimal training, take little time to administer, and are thus feasible in the clinical management of BD, 
these tools also have important limitations: They do not measure real life functions and cannot replace 
a comprehensive neuropsychological evaluation, which would give more detailed insight into which 
specific cognitive deficits may be related to the patients’ particular psychosocial difficulties (44). The 
SCIP is therefore not a substitute for a comprehensive neuropsychological examination, but is merely a 
useful initial tool to screen patients who may benefit from a more thorough assessment to rule out 
cerebral pathology. For example, in cases where rapid declines in cognitive function occur (and/or 
accompanied by other symptoms such as confusion, headache etc.) or when function is highly 
discordant with current mood state/function, brief screening would not be adequate. Brief cognitive 
screening therefore cannot replace such full diagnostic evaluations, and if they show some clear 
deficits, this may also trigger a referral for a more comprehensive specialist assessment. 
 
(III) What are the implications if cognitive impairment is detected on a brief tool? 
It may be argued that clinicians should not screen for something if they do not have management 
options for the condition. While there are several promising candidate cognition treatments currently 
under evaluation, we currently do not have any clinically available treatment with direct pro-cognitive 
effects (20;45). Nevertheless, cognitive screening assessments can still improve the clinical 
management of BD in three important ways.  
Referral to a thorough neuropsychological evaluation 
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First, detection of marked cognitive impairment with a cognitive screener provides a basis for referral 
to a thorough neuropsychological evaluation by trained neuropsychologists in certain cases. 
Specifically, circumstances that could warrant such a referral in the face of a ‘positive screen’ may 
include: (i) when there is a substantial impairment in the screening,  (ii) when there is a perception of 
worsening in either cognition or functioning in patients assessed in the past, (iii) when there is a query 
about the potential organic brain illness due to a comorbid condition (e.g. substance abuse, traumatic 
brain illness, or dementing process), (iv) when there is a desire to evaluate multiple cognitive domains 
implicated in bipolar disorder (e.g. sustained attention, verbal and nonverbal declarative memory,  
multiple executive functions including response inhibition, fluency, working memory, attentional 
shifting, mental flexibility, organization, and planning) for treatment or rehabilitative purposes, (v) 
when there are concerns about the patient’s motivation or effort during cognitive screening and thus the 
validity of test results, or (vi) when there are likely premorbid/developmental/learning problems that 
may complicate the cognitive picture. 
Evaluation of ‘secondary’ causes of cognitive deficits 
Second, cognitive screening during partial or full remission can provide a basis for evaluation of the 
potential impact of medical or psychiatric comorbidity, and medication on cognition. Clinicians could 
be prompted by a positive screen to ascertain for potential ‘secondary’ causes of cognitive deficits due 
to psychiatric comorbidity (e.g., alcohol use disorder or ADHD), medical comorbidity (e.g., 
cerebrovascular disease, diabetes, elevated ammonia levels or uncontrolled hypothyroidism), 
substantial subthreshold depressive symptoms and medications (e.g., antipsychotics, elevated serum 
levels of lithium or anticonvulsants, and benzodiazepines). This can be useful for optimization of 
patients’ treatments to reduce cognitive impairments; for example, reducing antipsychotic medication 
and benzodiazepine use or ensuring that serum mood stabilizer levels are within the recommended 
range. It is important to consider and address these common causes of secondary or pseudo-specific 
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cognitive deficits before a ‘true’ illness-associated cognitive impairment can be assumed. In many 
cases, addressing such secondary causes of cognitive deficits will result in significant cognitive 
improvement. 
Patient recommendations 
Detection of persistent cognitive impairments can provide a basis for recommendation of 
compensational strategies, adjustment of work responsibilities or rehabilitative interventions to 
improve functioning. Specifically, the assessments can be used to inform patients and their relatives 
about the nature and consequences of cognitive impairment which may help patients tackle and 
compensate for these difficulties in daily life. By increasing patients’ and their families’ insight into the 
nature and impact of residual cognitive impairments, the assessments may encourage patients to 
implement compensation strategies and reduce potential interpersonal problems (for example, family 
members’ irritation or disappointment when patients forget daily chores or anniversaries). When 
patients wish to resume work, brief assessment of their cognitive status can become an important basis 
for adjustment of work demands and reduce expectations so they are realistic. Finally, cognitive 
screening assessment can also provide impetus for good habits including getting regular and sufficient 
sleep and physical exercise, restricting alcohol intake, and adhering to treatment.  
Another important way of reducing cognitive impairment in bipolar disorder is implementation of 
strategies to boost patients’ cognitive reserve, the capacity of the brain to tolerate neuropathology, 
reduce symptom manifestations and manage cognitive challenges (46). Specifically, high cognitive 
reserve – which is estimated by patients’ premorbid IQ, educational level and occupational 
attainment(47) – is thought to slow down the clinical presentation of neurocognitive decline whereas 
low cognitive reserve may exacerbate cognitive decline (46;48). Cognitive screening assessments can 
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motivate patients to build up their cognitive reserve to prevent further cognitive decline and even 
improve their cognitive outcome.  
 
(IV) What are the treatment perspectives? 
There are no available treatments with documented direct pro-cognitive effects in bipolar disorder 
despite the pressing need for such treatments to enhance functional recovery and reduce societal costs 
(20). The unmet clinical need is partially due to several major methodological challenges in cognition 
trials in bipolar disorder, which have been addressed and discussed by the task force in a recently 
published methodological guidance paper (20). However, current research effort is likely to reveal 
effective pharmacological and psychological treatments within the next few years. 
Promising pharmacological treatments 
Among the most promising candidate pharmacological treatments are the corticosteroid receptor 
antagonist mifepristone, the atypical antipsychotic lurasidone, the multifunctional neurotrophic growth 
factor erythropoietin (EPO), the antidepressant vortioxetine and non-amphetamine stimulant modafinil. 
In particular, two studies of mifepristone (a one-week cross-over study and a three-week parallel study) 
in moderately depressed patients with bipolar disorder found beneficial effects on spatial working 
memory (but not on other cognitive domains) (49;50). Further, a recent randomized, open-label study 
recently found beneficial effects of six weeks treatment with lurasidone on a global measure of 
cognition in euthymic patients with bipolar disorder type I (51). A large multicenter RCT of six weeks 
lurasidone treatment for cognitive impairment in bipolar disorder is underway 
(https://clinicaltrials.gov/ct2/show/NCT02731612). Finally, two parallel RCTs investigating the effects 
of EPO trials in partially remitted patients with bipolar disorder and in treatment-resistant unipolar 
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depression revealed beneficial effects across several cognitive domains (52-54). Based on this, two new 
parallel RCTs have recently been initiated to examine the effects of 12-weeks EPO treatment of 
cognitively impaired patients with bipolar disorder and their first-degree relatives, respectively 
(Petersen et al, in prep.). In addition to the above mentioned candidate treatments with preliminary 
evidence for efficacy on cognition in bipolar disorder, there are several compounds that have shown 
promising effects in unipolar disorder. Modafinil – which was originally intended to treat narcolepsy – 
is a promising candidate treatment based on findings from a recent RCT in remitted patients with 
unipolar disorder. Specifically, beneficial effects of a single dose (200 mg) modafinil over placebo 
were observed on episodic memory and working memory (but not on executive function or sustained 
attention) in these remitted patients (55). Further, the antidepressant vortioxetine was found in several 
RCTs to improve some aspects of cognition in unipolar disorder, which seems to be partially 
independent of its antidepressant actions and was also recently shown in remitted patients (56;57). 
Studies are therefore warranted to investigate the ability of these compounds to improve cognitive 
function in bipolar disorder.  
Promising psychological treatments 
Promising psychological treatments for cognitive and functional impairments in bipolar disorder are 
functional remediation (FR) and certain cognitive remediation (CR) programs including action-based 
cognitive remediation (ABCR). Functional remediation and ABCR both involve cognitive training, 
compensation techniques and coping strategies to overcome cognitive difficulties in daily life 
situations. However, while FR focuses primarily on the training of neurocognitive strategies and 
psychosocial skills (58), ABCR emphasizes computerized cognitive training and transfer of the learned 
skills to daily life challenges by practical in-session exercises and actively seeking cognitive challenges 
in daily life. Functional remediation seems a viable option for patients presenting cognitive and 
psychosocial impairments because it has shown to be effective at improving functioning in patients in 
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late states of illness (58;59). While a large RCT did not show significant benefits of 21 weeks FR on 
cognition, this may be because of the study design that involved enrichment for functional impairment 
but not for cognitive deficits (58). Indeed, exclusion of the patients who were cognitively intact 
revealed a significant treatment benefit on verbal memory function (60). In addition, several 
naturalistic or quasi-experimental studies of different CR programs for bipolar disorder have been 
investigated over the past decade with encouraging preliminary results (61-65), although the only 
published RCT of 12-weeks group-based CR showed no efficacy on objective cognition (66). Notably, 
a non-randomized controlled trial of 10 weeks of ABCR was recently found to improve not only 
cognition but also vocational function in a mixed group of patients with severe mental illnesses 
(schizophrenia, unipolar and bipolar disorder) (67). Based on this evidence, two parallel RCTs were 
recently set up to investigate the effects of 10 weeks ABCR in cognitively impaired patient with bipolar 
disorder in remission and their first-degree relatives (68). Other ongoing RCTs investigate the effects 
of 12 weeks of cognitive-behavioral rehabilitation (69), 12 weeks of cognitive remediation (70) and 24 
weeks internet-based cognitive remediation for BD I (71). 
A highly promising treatment perspective is the combination of pharmacological and psychological 
interventions (e.g., (72)). This is likely to produce synergistic effects on brain function that may 
translate into more robust efficacy on cognition and functional outcome than either treatment modality 
alone. Multimodal treatment approaches are therefore considered a key next step for cognition trials in 
bipolar disorder that is likely to reveal new effective treatment options.  
 
4. Conclusions  
Cognition is a new key treatment target in bipolar disorder but there has been a lack of consensus on 
how cognitive impairment should be assessed and managed. This ISBD Targeting Cognition Task 
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Force paper provides the first consensus-based recommendations for clinicians on whether and how to 
assess and address cognition in their patients. The task force addressed questions about (I) whether and 
when to conduct cognitive screening assessments, (II) what screening tools are most feasible, (III) what 
the implications are if impairment is detected, and (IV) which treatment perspectives there are for 
improving cognition and functioning in BD. The recommendations are summarized in Table 1 and 
displayed in Figure 1. Key recommendations are that clinicians: (I) conduct formal assessment of 
cognition for all patients in partial or full remission whenever possible, (II) use brief, feasible tools that 
include objective and subjective cognition measures such as the SCIP and COBRA, which exist in 
multiple languages and are freely available through the ISBD website, (III) evaluate the potential 
impact of medication, comorbidity and symptoms when impairment is detected, refer for more 
comprehensive neuropsychological evaluation when clinically indicated, use the assessments to 
encourage patients to build up their cognitive reserve. Regarding (IV), there is currently no clinically 
available treatment with efficacy on cognition but intense research effort is likely to reveal new 
effective pharmacological, psychological and multimodal treatments in the near future.  
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Table 1: Quick guide with a summary of the ISBD task force recommendations. 
 
Clinical Recommendations for Assessment of Cognition in Bipolar Disorder by the International 
Society for Bipolar Disorders Targeting Cognition Task Force 
Quick guide 
(I) Should cognitive screening assessments be conducted?  
 Conduct formal screening assessment of cognition for all patients in partial or full remission 
whenever possible since subjective and objective cognition measures correlate poorly 
 Assess objective and subjective cognition to: (i) detect cognitive impairment that should be 
addressed and in some cases may require referral for comprehensive neuropsychological 
evaluation, (ii) identify those who are cognitively intact, and (iii) track cognition, ideally at least 
every 5 years or whenever there is a reason to anticipate the assessment  
(II) What are the most feasible tools? 
 Use brief, feasible tools that include objective and subjective cognition measures such as the 
Screen for Cognitive Impairment in Psychiatry (SCIP) and  Cognitive Complaints in Bipolar 
Disorder Rating Assessment (COBRA) 
 Obtain the SCIP and COBRA- which exist in multiple languages and are freely available - 
through the ISBD website at (URL)  
(III) What are the implications if cognitive impairment is detected?  
 Evaluate the potential impact of medication, comorbidity and symptoms when impairment is 
detected to discriminate between ‘secondary’ and ‘primary’ causes of cognitive impairments – 
and adjust medication if necessary to reduce cognitive side-effects 
 Consider referral for more comprehensive neuropsychological evaluation when there is a 
substantial impairment in the screening, when there is concern of organic brain illness, 
comorbidity, or cognitive decline, when there is a need to evaluate multiple cognitive domains 
in greater detail, when there is a question of poor effort affecting validity of test results, or when 
premorbid/developmental/learning problems may be complicating the cognitive picture. 
 Inform patients and relatives about the nature and possible consequences of patients’ cognitive 
impairments and encourage compensation strategies, support and adjustment of expectations 
 Encourage patients  to implement good habits, including regular sleep and exercise and to build 
up their cognitive reserve by engaging in education and vocational activities 
(IV) What are the treatment perspectives? 
 There is currently no clinically available treatment with efficacy on cognition but intense 
research effort is likely to reveal effective treatments within the next few years 
 Promising pharmacological candidate treatments are: mifepristone, lurasidone, erythropoietin 
(EPO), vortioxetine and modafinil 
 Promising psychological interventions are functional remediation and cognitive remediation 
programs including action-based cognitive remediation 
